KUALA LUMPUR, Aug 14 (Bernama) -- SBC Medical Group Holdings Inc (SBC Medical) reported a 13 per cent year-on-year (yoy) increase in consolidated revenue to US$49 million for the second quarter (Q2) of fiscal 2026 ended June 30. (US$1 = RM4.08)
Net income attributable to SBC Medical surged 335 per cent yoy to US$11 million, while adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) increased 32 per cent to US$20 million.
Basic earnings per share jumped 400 per cent year-on-year to US$0.10, while net income margin increased 16 percentage points to 22 per cent and adjusted EBITDA margin climbed six percentage points to 41 per cent.
In a statement, SBC Medical Chairman and Chief Executive Officer, Yoshiyuki Aikawa said the company was increasingly confident that its growth reacceleration reflected strengthening underlying fundamentals, with the convergence of healthcare and artificial intelligence (AI) becoming a source of competitive advantage.
He said the company is leveraging more than 26 years of accumulated management data to develop AI-enabled services, including AI-powered call centres, AI-driven marketing and AI-assisted site selection for new clinics.
The company said the quarter marked a reacceleration in growth, supported by the expansion of its points business following a change in operating policy and higher service fees driven by enhanced AI-enabled support capabilities.
The medical corporations supported by SBC Medical also continued to expand, with the number of locations increasing by 34 yoy to 287 as of end-June. Last-12-month patient visits reached 6.9 million, up 10 per cent yoy, while average spending per visit rose nine per cent to US$287.
The company said fee revisions for call centre services provided to five affiliated medical corporations, together with separate fee revisions reflecting expanded support for Rize Clinic and Gorilla Clinic, are expected to increase annual service fees by approximately US$15 million if their impact is realised for a full year.
Looking ahead, SBC Medical said it will deepen its multi-brand strategy in aesthetic dermatology in Japan, expand its non-aesthetic business and accelerate international growth through its collaboration with OrangeTwist in the United States and expansion in Southeast Asia, anchored in Thailand. The company also plans to enter the longevity market.
-- BERNAMA